RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Royalty Pharma plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$60.27−0.69 (-1.13%)
Close on Oct 19, 2026
- Market cap
- $33.56B
- P/E (TTM)
- 34.2
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2017 to 2025
Operating margin
65.6%−9.6 pts over 5 years
Net margin
32.4%−13.5 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +5.1% | +2.1% | +2.3% | – | |
| Operating income | +20.7% | +71.9% | -0.5% | – | |
| Net income | -10.2% | +162.1% | -4.6% | – | |
| EPS, diluted | -6.8% | +161.1% | +6.2% | – |
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on assets | – | 6.8% | 4.1% | |
| Current ratio | – | 8.76 | 2.40 | |
| Interest coverage | – | 10.2× | 5.1× | |
| Diluted shares | – | 375M | 564M |
Cash use needs five years of cash flow figures
Royalty Pharma does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$770.95M
- Cash generatingOperating cash flow above zero$2.49B
- Return on assets improvedROA up on the prior year5.2% → 4.2%
- Earnings backed by cashOperating cash flow above net income$2.49B vs $770.95M
- Less leverageLong-term debt to assets fell36.3% → 43.7%
- Better liquidityCurrent ratio rose1.44 → 2.40
- No dilutionShare count did not rise594M → 564M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.14 → 0.13